Murphy Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Murphy Capital Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-2,052	Closed	-$135K	–	318
2016 Q1	$135K	Hold	2,052	–	–	0.02%	287
2015 Q4	$127K	Hold	2,052	–	–	0.02%	306
2015 Q3	$137K	Hold	2,052	–	–	0.02%	281
2015 Q2	$199K	Hold	2,052	–	–	0.03%	304
2015 Q1	$191K	Hold	2,052	–	–	0.03%	315
2014 Q4	$182K	Hold	2,052	–	–	0.03%	319
2014 Q3	$141K	Hold	2,052	–	–	0.02%	326
2014 Q2	$117K	Hold	2,052	–	–	0.02%	329
2014 Q1	$81K	Hold	2,052	–	–	0.01%	320
2013 Q4	$86K	Hold	2,052	–	–	0.01%	312
2013 Q3	$61K	Hold	2,052	–	–	0.01%	300
2013 Q2	$108K	Buy	+2,052	New	+$89.9K	0.02%	287

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

LIM

Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return

Murphy Capital Management's MACK Position: Q2 2016 in Review

Murphy Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2016, closing a stake of 2,052 shares — an estimated $135K sold.

Murphy Capital Management first reported a position in MACK in Q2 2013 and held it in 12 quarters. The position peaked at $199K in Q2 2015. 140 funds tracked by Wall St. Rank hold MACK as of Q2 2016.

Murphy Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
Murphy Capital Management sold 2,052 Merrimack Pharmaceuticals, Inc. shares in Q2 2016, an estimated $135K.
Murphy Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 12 quarters.
Murphy Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $199K in Q2 2015.
140 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2016.

Based on Murphy Capital Management's 13F filing for Q2 2016, filed 19 Jul 2016.